"Rifampin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)
MeSH Number(s)
D03.549.811.700
D04.345.295.750.700
Below are MeSH descriptors whose meaning is more general than "Rifampin".
Below are MeSH descriptors whose meaning is more specific than "Rifampin".
This graph shows the total number of publications written about "Rifampin" by people in Harvard Catalyst Profiles by year, and whether "Rifampin" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 |
| 1994 | 2 | 1 | 3 |
| 1996 | 1 | 1 | 2 |
| 1997 | 1 | 1 | 2 |
| 1998 | 4 | 1 | 5 |
| 2001 | 2 | 1 | 3 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 5 | 5 |
| 2004 | 3 | 4 | 7 |
| 2005 | 1 | 6 | 7 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 1 | 2 |
| 2009 | 0 | 3 | 3 |
| 2010 | 0 | 3 | 3 |
| 2011 | 5 | 7 | 12 |
| 2012 | 4 | 5 | 9 |
| 2013 | 1 | 5 | 6 |
| 2014 | 6 | 4 | 10 |
| 2015 | 0 | 4 | 4 |
| 2016 | 5 | 4 | 9 |
| 2017 | 8 | 6 | 14 |
| 2018 | 5 | 8 | 13 |
| 2019 | 8 | 8 | 16 |
| 2020 | 3 | 10 | 13 |
| 2021 | 6 | 12 | 18 |
| 2022 | 1 | 2 | 3 |
Below are the most recent publications written about "Rifampin" by people in Profiles.
-
Early mortality during rifampicin-resistant TB treatment. Int J Tuberc Lung Dis. 2022 Feb 01; 26(2):150-157.
-
Tuberculosis Pathways to Care and Transmission of Multidrug Resistance in India. Am J Respir Crit Care Med. 2022 01 15; 205(2):233-241.
-
Pharmacogenetics of interaction between depot medroxyprogesterone acetate and efavirenz, rifampicin, and isoniazid during treatment of HIV and tuberculosis. Pharmacogenet Genomics. 2022 01 01; 32(1):24-30.
-
Safety and Effectiveness of an All-Oral, Bedaquiline-Based, Shorter Treatment Regimen for Rifampicin-Resistant Tuberculosis in High Human Immunodeficiency Virus (HIV) Burden Rural South Africa: A Retrospective Cohort Analysis. Clin Infect Dis. 2021 11 02; 73(9):e3563-e3571.
-
"This is not my body": Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis. PLoS One. 2021; 16(10):e0251482.
-
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial. Trials. 2021 Sep 25; 22(1):651.
-
Cost of Delivering 12-Dose Isoniazid and Rifapentine Versus 6 Months of Isoniazid for Tuberculosis Infection in a High-Burden Setting. Clin Infect Dis. 2021 09 07; 73(5):e1135-e1141.
-
High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial. Clin Infect Dis. 2021 09 07; 73(5):876-884.
-
Diagnosis patterns for rifampicin-resistant TB after onset of COVID-19. Int J Tuberc Lung Dis. 2021 09 01; 25(9):772-775.
-
Whole genome sequencing of clinical samples reveals extensively drug resistant tuberculosis (XDR TB) strains from the Beijing lineage in Nigeria, West Africa. Sci Rep. 2021 08 30; 11(1):17387.